Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07309822) titled 'Study to Assess the Safety and Effectiveness of Beltaven(R) in Patients With Allergy to Apis Mellifera, Polistes Dominula or Vespula Spp' on Dec. 16, 2025.
Study Type: Observational
Primary Sponsor: Probelte Pharma S.L.U.
Condition:
Allergy
Recruitment Status: Recruiting
Date of First Enrollment: February 1, 2025
Target Sample Size: 27
Countries of Recruitment:
Spain
To know more, visit https://clinicaltrials.gov/study/NCT07309822
Disclaimer: Curated by HT Syndication....